View the full webinar on PsychU: https://bit.ly/3t5oeuU
Schizophrenia has a worldwide prevalence of approximately 1%. Individuals living with the disease often experience neurocognitive deficits, as well as poor memory and attention, which are considered core symptoms for the illness. Current evidence also suggests that neuroinflammation, a byproduct of neurotransmitter dysfunctions as a result of increased pro-inflammatory cytokines, may play a role in cognitive dysfunction and neurodegeneration in serious mental illnesses, such as schizophrenia.
Recent evidence suggests that cognitive deficits may be present even before the onset of illness, making them targets for potential early intervention.2 Neuroprotective strategies that aim to address these factors exist. However, these treatments have limitations.
In this webinar, hear from Dr. René Kahn and Dr. Christoph Correll, as they discuss the trajectory of cognition in the course of illness for schizophrenia and describe potential strategies for measuring cognition. Speakers will also explore the evidence surrounding impacts to patient functioning and address the benefits and risks of a variety of potential neuroprotective strategies.
#MentalHealth #Schizophrenia #NeurocognitiveDeficits #NeuroprotectiveStrategies #cognition
Christoph Correll, M.D., is a Professor of Psychiatry at Hofstra Northwell School of Medicine in New York, NY. He also serves as the Medical Director of the Recognition & Prevention (RAP) Program at the Zucker Hillside Hospital. Dr. Correll completed his medical studies at the Free University of Berlin in Germany, and the Dundee University Medical School in Scotland. He completed both a general psychiatry residency and a child and adolescent psychiatry fellowship at Zucker Hillside Hospital.
René Kahn, M.D., Ph.D., is the Esther & Joseph Klingenstein Professor and System Chair of Psychiatry at the Icahn School of Medicine at Mount Sinai. Dr. Kahn is an Honorary Lifetime Professor at Jilin University, as well as a Fellow of the American College of Neuropsychopharmacology. In 2015 and 2016, he was named as a Thomson Reuters’ Highly Cited Researcher. Dr. Kahn completed his medical studies in the Netherlands and was trained as a psychiatrist and neurologist in Utrecth and Amsterdam. He completed a research fellowship in biological psychiatry at Albert Einstein College of Medicine, and a psychiatry residency at Mount Sinai Hospital.
Speakers are paid consultants to Otsuka Pharmaceutical Development & Commercialization, Inc.
PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU's educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.
View the full webinar on PsychU: https://bit.ly/3t5oeuU
MRC2.CORP.X.03548
Информация по комментариям в разработке